Production (Stage)
CG Oncology, Inc.
CGON
$25.46
-$0.40-1.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -96.30% | -93.47% | -94.94% | -- | -- |
| Total Depreciation and Amortization | 225.00% | 100.00% | 125.00% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -152.94% | -- | -- |
| Total Other Non-Cash Items | 2,373.69% | 1,273.76% | -137.64% | -- | -- |
| Change in Net Operating Assets | 328.49% | -19.60% | -74.44% | -- | -- |
| Cash from Operations | -37.94% | -90.11% | -116.44% | -- | -- |
| Capital Expenditure | -1,222.22% | -3,800.00% | -400.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.70% | -680.58% | -170.73% | -- | -- |
| Cash from Investing | 32.61% | -681.06% | -170.74% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 97.86% | 97.82% | -- | -- |
| Issuance of Common Stock | -44.38% | 112,167.85% | 90,972.61% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -99.28% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.13% | 3.85% | -1,373.63% | -- | -- |
| Cash from Financing | -41.09% | 3,297.19% | 906.36% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -163.05% | 349.90% | 132.17% | -- | -- |